Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 15/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071018 | 0.92 | KMT2A (0.42) | MPLKDM4EKMT2AB3GNT2PARP1 | |
| SCHEMBL6070804 | 0.89 | MPL (0.51) | MPLKDM4EKMT2APARP1RET | |
| SCHEMBL6071082 | 0.83 | MPL (0.54) | MPLKDM4EKMT2APARP1RET | |
| SCHEMBL6071372 | 0.81 | GSK3B (0.43) | MPLKDM4EKMT2APARP1 | |
| SCHEMBL6070685 | 0.78 | PARP1 (0.36) | MPLPARP1 | |
| SCHEMBL6071286 | 0.75 | GSK3B (0.45) | MPLKDM4EKMT2APARP1 | |
| SCHEMBL6070880 | 0.73 | MPL (0.57) | MPLPARP1 | |
| SCHEMBL6071582 | 0.68 | CYP19A1 (0.45) | KDM4EKMT2A | |
| SCHEMBL6449055 | 0.65 | HSD17B10 (0.59) | MPLKDM4EKMT2APARP1 | |
| SCHEMBL6070734 | 0.64 | GSK3B (0.47) | MPLKDM4EKMT2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | MPL 1056/4885KDM4E 1799/4885KMT2A 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.